Theriva Biologics (TOVX) investor relations material

Executive summary

• Focus shifted to oncology with lead candidate VCN-01, an oncolytic adenovirus, advancing in pancreatic cancer and retinoblastoma clinical trials, with FDA alignment on Phase 3 trial design and new data presented at AACR 2026.

• Out-licensed SYN-020 to Rasayana Therapeutics, securing $300,000 upfront and potential milestones and royalties.

• Workforce reduction and cost-saving measures implemented to extend cash runway into Q1 2027, with cash and cash equivalents of $14.4 million as of March 31, 2026.

• Compassionate use of VCN-01 in retinoblastoma initiated, with feasibility and tolerability data expected to inform a potential Phase 2/3 trial.

Financial highlights

• License revenue of $300,000 recognized in Q1 2026 from the SYN-020 out-license.

• Net loss for Q1 2026 was $2.0 million, a significant improvement from $4.3 million in Q1 2025.

• Cash and cash equivalents at March 31, 2026 were $14.4 million, up from $13.1 million at year-end 2025.

• Research and development expenses decreased 88% year-over-year to $355,000 due to completion of major trials and recognition of Spanish R&D rebate.

• General and administrative expenses increased 43% year-over-year to $2.1 million, mainly from higher legal, IR, registration, and salary costs.

Outlook and guidance

• Current cash expected to fund operations into Q1 2027, covering overhead, a Phase 2a VCN-01 study, manufacturing scale-up, and regulatory interactions.

• Phase 3 VCN-01 trial in metastatic PDAC to commence after feasibility study in Spain in H2 2026; Phase 2/3 trial protocol for VCN-01 plus topotecan in retinoblastoma under development.

• Rolling BLA submissions for VCN-01 in retinoblastoma anticipated in 2029, aiming for approval before September 30, 2029.

• Additional funding required for larger Phase 3 trials and further development of SYN-004 and VCN-01 beyond planned studies.

• Actively pursuing strategic alternatives, partnerships, and additional financing; no assurance of success.